GSK said that IDRX-42 addresses all the key KIT mutations that drive tumour growth ... as well as competition to shingles vaccine Shingrix, currently its top product, from the likes of Pfizer ...
The proceeds were earmarked for the ongoing phase 1/1b StrateGIST 1 trial of the selective KIT inhibitor in patients ... as well as competition to shingles vaccine Shingrix, currently its top ...
Are you looking for Microsoft Store in: {0}?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results